연구동향 분석
박사

섬유성 망막 질환에서 전이성장인자 신호전달과정 억제를 통한 항섬유화 약물 (pirfenidone)의 효과 및 기전 : Effect of Anti-fibrotic Drug (Pirfenidone) on TGF-β Signaling Pathway in Ocular Fibrotic Disorders

이기황 2015년

논문상세정보
인용/피인용
' 섬유성 망막 질환에서 전이성장인자 신호전달과정 억제를 통한 항섬유화 약물 (pirfenidone)의 효과 및 기전 : Effect of Anti-fibrotic Drug (Pirfenidone) on TGF-β Signaling Pathway in Ocular Fibrotic Disorders' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • cell singnal
  • epithelial-mesenchymal transition
  • fibrosis
  • pirfenidone
  • retinal pigment epithelial (rpe) cells
  • transforming growth factor-β (tgf-β)
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
88 0

0.0%

' 섬유성 망막 질환에서 전이성장인자 신호전달과정 억제를 통한 항섬유화 약물 (pirfenidone)의 효과 및 기전 : Effect of Anti-fibrotic Drug (Pirfenidone) on TGF-β Signaling Pathway in Ocular Fibrotic Disorders' 의 참고문헌

  • Zhang S, Shiels IA, Ambler JS, Taylor SM: Pirfenidone reduces fibronectinsynthesis by cultured human retinal pigment epithelial cells. Aust N Z J Ophthalmol 26Suppl 1: S74-76, 1998
  • Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, Kalluri R:Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition.J Biol Chem 282: 23337-23347, 2007
  • Yu L, Hebert MC, Zhang YE: TGF-beta receptor-activated p38 MAP kinasemediates Smad-independent TGF-beta responses. EMBO J 21: 3749-3759, 2002
  • Yang Y, Ye Y, Lin X, Wu K, Yu M: Inhibition of pirfenidone on TGF-beta2induced proliferation, migration and epithlial-mesenchymal transition of human lensepithelial cells line SRA01/04. PLoS One 8: e56837, 2013
  • Yang J, Liu Y: Dissection of key events in tubular epithelial to myofibroblasttransition and its implications in renal interstitial fibrosis. Am J Pathol 159: 1465-1475, 2001
  • Xu J, Lamouille S, Derynck R: TGF-beta-induced epithelial to mesenchymaltransition. Cell Res 19: 156-172, 200949
  • Wang Y, Wu Y, Chen J, Zhao S, Li H: Pirfenidone attenuates cardiac fibrosis in amouse model of TAC-induced left ventricular remodeling by suppressing NLRP3inflammasome formation. Cardiology 126: 1-11, 2013
  • Wang W, Eddy R, Condeelis J: The cofilin pathway in breast cancer invasion andmetastasis. Nat Rev Cancer 7: 429-440, 2007
  • Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat RevCancer 2: 442-454, 2002
  • Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymaltransitions. Nat Rev Mol Cell Biol 7: 131-142, 2006
  • Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitionsin development and disease. Cell 139: 871-890, 2009
  • Song S, Kang SW, Choi C: Trichostatin A enhances proliferation and migration ofvascular smooth muscle cells by downregulating thioredoxin 1. Cardiovasc Res 85: 241-249,2010
  • Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K:Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 54:99-109, 1998
  • Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, Shirai K,Yamauchi S, Margolin SB, Shimizu F, Kurokawa K: Pirfenidone prevents collagenaccumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 63:S239-243, 1997
  • Shihab FS, Bennett WM, Yi H, Andoh TF: Pirfenidone treatment decreasestransforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chroniccyclosporine nephrotoxicity. Am J Transplant 2: 111-119, 2002
  • Sheridan CM, Occleston NL, Hiscott P, Kon CH, Khaw PT, Grierson I: Matrixmetalloproteinases: a role in the contraction of vitreo-retinal scar tissue. Am J Pathol 159:1555-1566, 2001
  • Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A: Targeted disruption ofTGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced byunilateral ureteral obstruction. J Clin Invest 112: 1486-1494, 200348
  • Saika S, Yamanaka O, Ikeda K, Kim-Mitsuyama S, Flanders KC, Yoo J, RobertsAB, Nishikawa-Ishida I, Ohnishi Y, Muragaki Y, Ooshima A: Inhibition of p38MAP kinasesuppresses fibrotic reaction of retinal pigment epithelial cells. Lab Invest 85: 838-850, 2005
  • Ryan SJ: The pathophysiology of proliferative vitreoretinopathy in its management.Am J Ophthalmol 100: 188-193, 1985
  • Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME: Thedifferential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses inhuman proximal-tubule epithelial cells. Biochem J 393: 601-607, 2006
  • Pennison M, Pasche B: Targeting transforming growth factor-beta signaling. CurrOpin Oncol 19: 579-585, 2007
  • Pastor JC, de la Rua ER, Martin F: Proliferative vitreoretinopathy: risk factors andpathobiology. Prog Retin Eye Res 21: 127-144, 2002
  • Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA: Focal adhesion kinase: aregulator of focal adhesion dynamics and cell movement. Oncogene 19: 5606-5613, 2000
  • Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S,Torii M, Arimura A: Antifibrotic action of pirfenidone and prednisolone: different effects onpulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.Eur J Pharmacol 590: 400-408, 2008
  • Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R: Pirfenidone suppressestumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.Eur J Pharmacol 446: 167-176, 2002
  • Okada H, Danoff TM, Kalluri R, Neilson EG: Early role of Fsp1 in epithelialmesenchymaltransformation. Am J Physiol 273: F563-574, 1997
  • Nobes CD, Hall A: Rho, rac, and cdc42 GTPases regulate the assembly ofmultimolecular focal complexes associated with actin stress fibers, lamellipodia, andfilopodia. Cell 81: 53-62, 1995
  • Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, Oku H,Urata Y, Kondo T, Kubota H, Nagata K, Kohno S: Pirfenidone inhibits the expression ofHSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 82: 210-217, 200847
  • Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S,Kawabata M, Heldin NE, Heldin CH, ten Dijke P: Identification of Smad7, a TGFbetainducibleantagonist of TGF-beta signalling. Nature 389: 631-635, 1997
  • Nagineni CN, Samuel W, Nagineni S, Pardhasaradhi K, Wiggert B, Detrick B,Hooks JJ: Transforming growth factor-beta induces expression of vascular endothelialgrowth factor in human retinal pigment epithelial cells: involvement of mitogen-activatedprotein kinases. J Cell Physiol 197: 453-462, 2003
  • Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T: Openlabelcompassionate use one year-treatment with pirfenidone to patients with chronicpulmonary fibrosis. Intern Med 41: 1118-1123, 2002
  • Misra HP, Rabideau C: Pirfenidone inhibits NADPH-dependent microsomal lipidperoxidation and scavenges hydroxyl radicals. Mol Cell Biochem 204: 119-126, 2000
  • Massague J, Seoane J, Wotton D: Smad transcription factors. Genes Dev 19: 2783-2810, 2005
  • Machemer R: Massive periretinal proliferation: a logical approach to therapy. TransAm Ophthalmol Soc 75: 556-586, 1977
  • Lo RS, Chen YG, Shi Y, Pavletich NP, Massague J: The L3 loop: a structural motifdetermining specific interactions between SMAD proteins and TGF-beta receptors. EMBO J17: 996-1005, 1998
  • Liao JH, Chen JS, Chai MQ, Zhao S, Song JG: The involvement of p38 MAPK intransforming growth factor beta1-induced apoptosis in murine hepatocytes. Cell Res 11: 89-94, 2001
  • Lee K, Young Lee S, Park SY, Yang H: Antifibrotic effect of pirfenidone on humanpterygium fibroblasts. Curr Eye Res 39: 680-685, 2014
  • Lee JM, Dedhar S, Kalluri R, Thompson EW: The epithelial-mesenchymaltransition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981,200646
  • Lee J, Ko M, Joo CK: Rho plays a key role in TGF-beta1-induced cytoskeletalrearrangement in human retinal pigment epithelium. J Cell Physiol 216: 520-526, 2008
  • Lamouille S, Derynck R: Cell size and invasion in TGF-beta-induced epithelial tomesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178:437-451, 2007
  • Kimoto K, Nakatsuka K, Matsuo N, Yoshioka H: p38 MAPK mediates theexpression of type I collagen induced by TGF-beta 2 in human retinal pigment epithelialcells ARPE-19. Invest Ophthalmol Vis Sci 45: 2431-2437, 2004
  • Kim H, Choi YH, Park SJ, Lee SY, Kim SJ, Jou I, Kook KH: Antifibrotic effect ofPirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy bydecreasing TIMP-1 and collagen levels. Invest Ophthalmol Vis Sci 51: 3061-3066, 2010
  • Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J ClinInvest 119: 1420-1428, 2009
  • Kakugawa T, Mukae H, Hayashi T, Ishii H, Abe K, Fujii T, Oku H, Miyazaki M,Kadota J, Kohno S: Pirfenidone attenuates expression of HSP47 in murine bleomycininducedpulmonary fibrosis. Eur Respir J 24: 57-65, 2004
  • Jaffe AB, Hall A: Rho GTPases: biochemistry and biology. Annu Rev Cell DevBiol 21: 247-269, 2005
  • Iyer SN, Gurujeyalakshmi G, Giri SN: Effects of pirfenidone on transforminggrowth factor-beta gene expression at the transcriptional level in bleomycin hamster modelof lung fibrosis. J Pharmacol Exp Ther 291: 367-373, 1999
  • Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence thatfibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350, 2002
  • Itoh Y, Kimoto K, Imaizumi M, Nakatsuka K: Inhibition of RhoA/Rho-kinasepathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinalpigment epithelial cells. Exp Eye Res 84: 464-472, 2007
  • Itoh S, Landstrom M, Hermansson A, Itoh F, Heldin CH, Heldin NE, ten Dijke P:Transforming growth factor beta1 induces nuclear export of inhibitory Smad7. J Biol Chem273: 29195-29201, 199845
  • Hisatomi K, Mukae H, Sakamoto N, Ishimatsu Y, Kakugawa T, Hara S, Fujita H,Nakamichi S, Oku H, Urata Y, Kubota H, Nagata K, Kohno S: Pirfenidone inhibits TGFbeta1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells.BMC Pulm Med 12: 24, 2012
  • Hinton DR, He S, Jin ML, Barron E, Ryan SJ: Novel growth factors involved in thepathogenesis of proliferative vitreoretinopathy. Eye (Lond) 16: 422-428, 2002
  • Hill CS: Nucleocytoplasmic shuttling of Smad proteins. Cell Res 19: 36-46, 2009
  • Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB, BeckerGJ: Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14:453-460, 2001
  • Hayashida T, Poncelet AC, Hubchak SC, Schnaper HW: TGF-beta1 activates MAPkinase in human mesangial cells: a possible role in collagen expression. Kidney Int 56: 1710-1720, 1999
  • Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA,Topper JN, Gimbrone MA, Jr., Wrana JL, Falb D: The MAD-related protein Smad7associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling.Cell 89: 1165-1173, 1997
  • Hartsough MT, Mulder KM: Transforming growth factor beta activation ofp44mapk in proliferating cultures of epithelial cells. J Biol Chem 270: 7117-7124, 1995
  • Gurujeyalakshmi G, Hollinger MA, Giri SN: Pirfenidone inhibits PDGF isoforms inbleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 276: L311-318, 1999
  • Grossniklaus HE, Green WR: Histopathologic and ultrastructural findings ofsurgically excised choroidal neovascularization. Submacular Surgery Trials Research Group.Arch Ophthalmol 116: 745-749, 1998
  • Garcia L, Hernandez I, Sandoval A, Salazar A, Garcia J, Vera J, Grijalva G, MurielP, Margolin S, Armendariz-Borunda J: Pirfenidone effectively reverses experimental liverfibrosis. J Hepatol 37: 797-805, 200244
  • Flanders KC: Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 85: 47-64, 2004
  • Ferris FL, 3rd, Fine SL, Hyman L: Age-related macular degeneration and blindnessdue to neovascular maculopathy. Arch Ophthalmol 102: 1640-1642, 1984
  • El-Sibai M, Pertz O, Pang H, Yip SC, Lorenz M, Symons M, Condeelis JS, HahnKM, Backer JM: RhoA/ROCK-mediated switching between Cdc42- and Rac1-dependentprotrusion in MTLn3 carcinoma cells. Exp Cell Res 314: 1540-1552, 2008
  • Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM: ARPE-19, a humanretinal pigment epithelial cell line with differentiated properties. Exp Eye Res 62: 155-169,1996
  • Dig Liver Dis 36: 744-751, 200414. Di Sario A, Bendia E, Svegliati Baroni G, Ridolfi F, Casini A, Ceni E, SaccomannoS, Marzioni M, Trozzi L, Sterpetti P, Taffetani S, Benedetti A: Effect of pirfenidone on rathepatic stellate cell proliferation and collagen production. J Hepatol 37: 584-591, 2002
  • Di Sario A, Bendia E, Macarri G, Candelaresi C, Taffetani S, Marzioni M,Omenetti A, De Minicis S, Trozzi L, Benedetti A: The anti-fibrotic effect of pirfenidone inrat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-
  • Connor TB, Jr., Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, deBustros S, Enger C, Kato H, Lansing M, et al.: Correlation of fibrosis and transforminggrowth factor-beta type 2 levels in the eye. J Clin Invest 83: 1661-1666, 1989
  • Choi YH, Back KO, Kim HJ, Lee SY, Kook KH: Pirfenidone attenuates IL-1betainducedCOX-2 and PGE2 production in orbital fibroblasts through suppression of NFkappaBactivity. Exp Eye Res 113: 1-8, 2013
  • Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB: Pirfenidone slows renalfunction decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol2: 906-913, 2007
  • Carrington L, McLeod D, Boulton M: IL-10 and antibodies to TGF-beta2 andPDGF inhibit RPE-mediated retinal contraction. Invest Ophthalmol Vis Sci 41: 1210-1216,200043
  • Campochiaro PA: Pathogenic mechanisms in proliferative vitreoretinopathy. ArchOphthalmol 115: 237-241, 1997
  • Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S, Lefkowitz SS:Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int JImmunopharmacol 20: 685-695, 1998
  • Bressler NM, Doan QV, Varma R, Lee PP, Suner IJ, Dolan C, Danese MD, Yu E,Tran I, Colman S: Estimated cases of legal blindness and visual impairment avoided usingranibizumab for choroidal neovascularization: non-Hispanic white population in the UnitedStates with age-related macular degeneration. Arch Ophthalmol 129: 709-717, 2011
  • Bressler NM, Bressler SB, Fine SL: Age-related macular degeneration. SurvOphthalmol 32: 375-413, 1988
  • Bochaton-Piallat ML, Kapetanios AD, Donati G, Redard M, Gabbiani G, PournarasCJ: TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast ofvitreoretinopathy. Invest Ophthalmol Vis Sci 41: 2336-2342, 2000
  • Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, ArteagaCL, Moses HL: Transforming growth factor-beta1 mediates epithelial to mesenchymaltransdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12: 27-36, 2001
  • Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S,Itoh H, Ohi M, Sato A, Kudoh S: Double-blind, placebo-controlled trial of pirfenidone inpatients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040-1047,2005
  • Artlett CM: Inflammasomes in wound healing and fibrosis. J Pathol 229: 157-167,2013